What is HC Wainwright’s Estimate for Lifeward Q3 Earnings?

Lifeward Ltd. (NASDAQ:LFWD) – HC Wainwright cut their Q3 2026 earnings per share (EPS) estimates for Lifeward in a report issued on Thursday, August 20th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.53) per share for the quarter, down from their prior estimate of ($0.42). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Lifeward’s current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Lifeward’s Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($0.44) EPS, Q1 2027 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.51) EPS, Q3 2027 earnings at ($0.52) EPS, Q4 2027 earnings at ($0.36) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($0.79) EPS, FY2029 earnings at $0.04 EPS and FY2030 earnings at $0.80 EPS.

Lifeward (NASDAQ:LFWD) last announced its earnings results on Saturday, August 15th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.07). Lifeward had a negative net margin of 141.28% and a negative return on equity of 235.86%. The business had revenue of $6.62 million for the quarter, compared to the consensus estimate of $6.53 million.

A number of other brokerages also recently commented on LFWD. Zacks Research upgraded Lifeward from a “strong sell” rating to a “hold” rating in a research report on Monday, July 27th. Weiss Ratings cut shares of Lifeward from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Finally, Citigroup restated a “buy” rating on shares of Lifeward in a research report on Friday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Lifeward has an average rating of “Hold” and an average price target of $10.00.

Lifeward Price Performance

Shares of Lifeward stock opened at $7.39 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.33 and a quick ratio of 1.77. The firm has a fifty day moving average price of $7.49 and a two-hundred day moving average price of $6.99. Lifeward has a fifty-two week low of $4.14 and a fifty-two week high of $10.56. The company has a market cap of $20.91 million, a PE ratio of -0.44 and a beta of 0.38.

Institutional Trading of Lifeward

Several institutional investors have recently added to or reduced their stakes in LFWD. Citadel Advisors LLC increased its holdings in shares of Lifeward by 1,271.8% during the third quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock worth $152,000 after purchasing an additional 198,406 shares during the period. HRT Financial LP boosted its position in Lifeward by 149.7% during the 4th quarter. HRT Financial LP now owns 49,081 shares of the company’s stock worth $28,000 after buying an additional 29,423 shares during the period. Jane Street Group LLC grew its stake in shares of Lifeward by 77.3% in the fourth quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after purchasing an additional 29,927 shares during the last quarter. Finally, Virtu Financial LLC lifted its position in shares of Lifeward by 158.0% in the 4th quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock worth $35,000 after purchasing an additional 37,037 shares during the period. 26.76% of the stock is currently owned by institutional investors.

Trending Headlines about Lifeward

Here are the key news stories impacting Lifeward this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.44 from a loss of $0.81, while improving its FY2028 estimate modestly to a loss of $0.79 from $0.83. The analyst also now expects Lifeward to reach profitability in FY2029 at $0.04 per share, versus a prior loss forecast of $0.64.
• Positive Sentiment: The firm increased its Q4 2027 estimate to a loss of $0.36 from $0.54 and continues to see longer-term earnings growth, forecasting $0.80 EPS in FY2030. The $10 target implies meaningful potential appreciation if Lifeward achieves the projected recovery.
• Neutral Sentiment: Reported short interest was listed at zero shares with a zero-day days-to-cover ratio, but the data also showed an invalid “NaN” change. Consequently, the short-interest update provides little reliable information about trading pressure.
• Negative Sentiment: HC Wainwright lowered estimates for several periods: Q3 and Q4 2026 EPS to losses of $0.53 and $0.57, respectively; Q1 and Q2 2027 to losses of $0.49 and $0.51; and FY2027 to a loss of $1.84 from $1.72. These cuts indicate weaker expected profitability before the projected turnaround.
• Negative Sentiment: The FY2030 EPS forecast was sharply reduced to $0.80 from $3.20, tempering the long-term outlook despite the continued Buy rating. Lifeward also recently reported a quarterly EPS loss wider than analysts expected, underscoring its high-risk, unprofitable profile.

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.